Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers
This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity and...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine (London, England) England), 2018-05, Vol.13 (10), p.1107-1120 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1120 |
|---|---|
| container_issue | 10 |
| container_start_page | 1107 |
| container_title | Nanomedicine (London, England) |
| container_volume | 13 |
| creator | Wang, Xin-shuai Zhang, Li Li, Xiaocen Kong, De-jiu Hu, Xiao-chen Ding, Xue-zhen Yang, Jun-qiang Zhao, Meng-qi He, Yixuan Lam, Kit S Gao, She-gan Lin, Tzu-yin Li, Yuanpei |
| description | This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.
We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity
and in lung cancer-bearing mice.
Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and
without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways.
The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients. |
| doi_str_mv | 10.2217/nnm-2017-0355 |
| format | Article |
| fullrecord | <record><control><sourceid>futurescience</sourceid><recordid>TN_cdi_futurescience_futuremedicine_10_2217_nnm_2017_0355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_nnm_2017_0355</sourcerecordid><originalsourceid>FETCH-futurescience_futuremedicine_10_2217_nnm_2017_03553</originalsourceid><addsrcrecordid>eNqlj8tOxDAMRSMEEsMMS_b5gUCS0mmzRDzEihUrWERW6o6CXBclqcT8PSnwB6zuuZZt6QhxZfS1taa7YZ6U1aZTumnbE7Ex3W2v9m7fnP5wo9q-d-fiIucPrdveGr0R7y_A8zinaSEoOMhPCBQLfCFJ4EHevT0464zMR8Z0iLnEAERHiQmGigUlz6zyVIcqIJGkhQ8yAAdMeSfORqCMl3-5Fe7p8fX-WY1LWRLmELHu-d82YX0YGb3RfrXx1cavNn61af5z-w1-clkS</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers</title><source>PubMed Central</source><creator>Wang, Xin-shuai ; Zhang, Li ; Li, Xiaocen ; Kong, De-jiu ; Hu, Xiao-chen ; Ding, Xue-zhen ; Yang, Jun-qiang ; Zhao, Meng-qi ; He, Yixuan ; Lam, Kit S ; Gao, She-gan ; Lin, Tzu-yin ; Li, Yuanpei</creator><creatorcontrib>Wang, Xin-shuai ; Zhang, Li ; Li, Xiaocen ; Kong, De-jiu ; Hu, Xiao-chen ; Ding, Xue-zhen ; Yang, Jun-qiang ; Zhao, Meng-qi ; He, Yixuan ; Lam, Kit S ; Gao, She-gan ; Lin, Tzu-yin ; Li, Yuanpei</creatorcontrib><description>This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.
We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity
and in lung cancer-bearing mice.
Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and
without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways.
The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.</description><identifier>ISSN: 1743-5889</identifier><identifier>EISSN: 1748-6963</identifier><identifier>DOI: 10.2217/nnm-2017-0355</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>AZD9291 ; EGFR inhibitor ; NSCLC ; paclitaxel</subject><ispartof>Nanomedicine (London, England), 2018-05, Vol.13 (10), p.1107-1120</ispartof><rights>2018 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Wang, Xin-shuai</creatorcontrib><creatorcontrib>Zhang, Li</creatorcontrib><creatorcontrib>Li, Xiaocen</creatorcontrib><creatorcontrib>Kong, De-jiu</creatorcontrib><creatorcontrib>Hu, Xiao-chen</creatorcontrib><creatorcontrib>Ding, Xue-zhen</creatorcontrib><creatorcontrib>Yang, Jun-qiang</creatorcontrib><creatorcontrib>Zhao, Meng-qi</creatorcontrib><creatorcontrib>He, Yixuan</creatorcontrib><creatorcontrib>Lam, Kit S</creatorcontrib><creatorcontrib>Gao, She-gan</creatorcontrib><creatorcontrib>Lin, Tzu-yin</creatorcontrib><creatorcontrib>Li, Yuanpei</creatorcontrib><title>Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers</title><title>Nanomedicine (London, England)</title><description>This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.
We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity
and in lung cancer-bearing mice.
Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and
without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways.
The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.</description><subject>AZD9291</subject><subject>EGFR inhibitor</subject><subject>NSCLC</subject><subject>paclitaxel</subject><issn>1743-5889</issn><issn>1748-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqlj8tOxDAMRSMEEsMMS_b5gUCS0mmzRDzEihUrWERW6o6CXBclqcT8PSnwB6zuuZZt6QhxZfS1taa7YZ6U1aZTumnbE7Ex3W2v9m7fnP5wo9q-d-fiIucPrdveGr0R7y_A8zinaSEoOMhPCBQLfCFJ4EHevT0464zMR8Z0iLnEAERHiQmGigUlz6zyVIcqIJGkhQ8yAAdMeSfORqCMl3-5Fe7p8fX-WY1LWRLmELHu-d82YX0YGb3RfrXx1cavNn61af5z-w1-clkS</recordid><startdate>20180501</startdate><startdate>20180601</startdate><enddate>20180501</enddate><enddate>20180601</enddate><creator>Wang, Xin-shuai</creator><creator>Zhang, Li</creator><creator>Li, Xiaocen</creator><creator>Kong, De-jiu</creator><creator>Hu, Xiao-chen</creator><creator>Ding, Xue-zhen</creator><creator>Yang, Jun-qiang</creator><creator>Zhao, Meng-qi</creator><creator>He, Yixuan</creator><creator>Lam, Kit S</creator><creator>Gao, She-gan</creator><creator>Lin, Tzu-yin</creator><creator>Li, Yuanpei</creator><general>Future Medicine Ltd</general><scope/></search><sort><creationdate>20180501</creationdate><title>Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers</title><author>Wang, Xin-shuai ; Zhang, Li ; Li, Xiaocen ; Kong, De-jiu ; Hu, Xiao-chen ; Ding, Xue-zhen ; Yang, Jun-qiang ; Zhao, Meng-qi ; He, Yixuan ; Lam, Kit S ; Gao, She-gan ; Lin, Tzu-yin ; Li, Yuanpei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-futurescience_futuremedicine_10_2217_nnm_2017_03553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>AZD9291</topic><topic>EGFR inhibitor</topic><topic>NSCLC</topic><topic>paclitaxel</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xin-shuai</creatorcontrib><creatorcontrib>Zhang, Li</creatorcontrib><creatorcontrib>Li, Xiaocen</creatorcontrib><creatorcontrib>Kong, De-jiu</creatorcontrib><creatorcontrib>Hu, Xiao-chen</creatorcontrib><creatorcontrib>Ding, Xue-zhen</creatorcontrib><creatorcontrib>Yang, Jun-qiang</creatorcontrib><creatorcontrib>Zhao, Meng-qi</creatorcontrib><creatorcontrib>He, Yixuan</creatorcontrib><creatorcontrib>Lam, Kit S</creatorcontrib><creatorcontrib>Gao, She-gan</creatorcontrib><creatorcontrib>Lin, Tzu-yin</creatorcontrib><creatorcontrib>Li, Yuanpei</creatorcontrib><jtitle>Nanomedicine (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xin-shuai</au><au>Zhang, Li</au><au>Li, Xiaocen</au><au>Kong, De-jiu</au><au>Hu, Xiao-chen</au><au>Ding, Xue-zhen</au><au>Yang, Jun-qiang</au><au>Zhao, Meng-qi</au><au>He, Yixuan</au><au>Lam, Kit S</au><au>Gao, She-gan</au><au>Lin, Tzu-yin</au><au>Li, Yuanpei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers</atitle><jtitle>Nanomedicine (London, England)</jtitle><date>2018-05-01</date><date>2018-06-01</date><risdate>2018</risdate><risdate>2018</risdate><volume>13</volume><issue>10</issue><spage>1107</spage><epage>1120</epage><pages>1107-1120</pages><issn>1743-5889</issn><eissn>1748-6963</eissn><abstract>This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.
We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity
and in lung cancer-bearing mice.
Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and
without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways.
The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/nnm-2017-0355</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-5889 |
| ispartof | Nanomedicine (London, England), 2018-05, Vol.13 (10), p.1107-1120 |
| issn | 1743-5889 1748-6963 |
| language | eng |
| recordid | cdi_futurescience_futuremedicine_10_2217_nnm_2017_0355 |
| source | PubMed Central |
| subjects | AZD9291 EGFR inhibitor NSCLC paclitaxel |
| title | Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T10%3A23%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoformulated%20paclitaxel%20and%20AZD9291%20synergistically%20eradicate%20non-small-cell%20lung%20cancers&rft.jtitle=Nanomedicine%20(London,%20England)&rft.au=Wang,%20Xin-shuai&rft.date=2018-05-01&rft.volume=13&rft.issue=10&rft.spage=1107&rft.epage=1120&rft.pages=1107-1120&rft.issn=1743-5889&rft.eissn=1748-6963&rft_id=info:doi/10.2217/nnm-2017-0355&rft_dat=%3Cfuturescience%3E10_2217_nnm_2017_0355%3C/futurescience%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |